PT-179 is an orthogonal thalidomide derivative used as a ligand for E3 ubiquitin ligase in PROTAC (proteolytic targeted chimera) technology. In PROTACs, PT-179 binds to CRBN, forms a ternary complex with the target protein fused to zinc finger (ZF) degron, and mediates the degradation of the tagged protein. This tagging process marks the target protein for degradation by the proteasome. By harnessing this mechanism, PT-179 is able to selectively remove proteins associated with various diseases, including cancer and neurodegenerative diseases. Therefore, PT-179 is a key component in the development of targeted protein degradation therapies.
Structure of 2924858-25-1
* For research and manufacturing use only. Not for human or clinical use.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
Please contact us with any specific requirements and we will get back to you as soon as possible.